Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis TCI604
- Development stage
- Preclinical
- Lead developer
- TCI
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis TCI604 is a probiotic bacterial strain originally isolated from human breast milk and developed by TCI CO., Ltd. as a live biotherapeutic product. The strain has been investigated for its potential to improve gastrointestinal health, specifically in reducing the incidence of colorectal polyps and colorectal cancer, as well as managing gastroesophageal reflux and digestive tract ulcers. TCI604 exerts its therapeutic effects by modulating the expression of various inflammatory and metabolic genes, including CRP, IL-1β, IL-8, IL-6, IL-10, IL-17A, TNF-α, CYP7A1, and APC. Research in animal models has demonstrated that both the live probiotic cells and their cell-free supernatant can attenuate systemic inflammation, gut dysbiosis, and the development of colonic precancerous lesions.
- Other names
- Bifidobacterium animalis subsp. lactis TCI604B. animalis subsp. lactis TCI604
02
Targets
APC (Activated protein C)IL10 (Interleukin-10)IL-17A (Interleukin-17A)IL-6 (Interleukin 6)CYP7A1 (Cholesterol 7alpha-hydroxylase)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis TCI604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis TCI604.